Stock fact sheet · data as of

Cingulate Inc. (CING): fair value, margin of safety and Wheel Score

Healthcare · Biotechnology · United States · Speculative / Distressed

Close4.39
GLS fair value0.05051 of 9 models
Margin of safety-8592%price above fair value
Wheel Score24Weakout of 100
Health2/9Piotroski F-score
Moat0.5/10GLS 10-year score
Market cap$64M176k shares a day
Implied vol.97%near-the-money, 20-60 d
P/E-EPS -5.30
Dividend yieldnone
Beta-0.88moves less than the market
Next earnings12 Nov 2026in 27 days (before the open)

Is CING undervalued?

CING closed at 4.39 on 16 Oct 2026, more than 30% above the GLS average fair value of 0.0505. Only 0 of the 1 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.

The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.

The nightly engine files CING under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for CING

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF0.0505-99%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-0.0382-101%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target9.00+105%Analysts' average 12-month price target. Not in the average

Quality and financial health

Cingulate Inc. scores only 2 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 0.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -198.8%, ROE -894.8%, ROA -148.9% - with debt at 3.50 times equity and negative free cash flow. Debt of 3.50 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.

Cingulate Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 3/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score2 / 9ROIC-198.8%
GLS Moat0.5 / 10ROE-894.8%
Debt / equity3.50ROA-148.9%
Free-cash-flow yield-32.8%Payout ratio0%
Institutions3 / 10Insiders · Congress10 · 5 / 10

Wheel Score 24: Weak

With a Wheel Score of 24 Cingulate Inc. sits in the Weak band. The parts - Value 0/25, Health 4/20, Moat 1/15, Premium 11/20, Stability 8/20 - show where: Value (0/25) scores lowest.

Implied volatility is 97% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (11 of 20) because volatility this high usually comes with a reason. Chain open interest is 13,276 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 176k shares a day on a market cap of $64M, with a beta of -0.88 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 8 of 20.

PartPointsFrom
Value0 / 25-8592% margin of safety
Health4 / 20Piotroski 2/9
Moat1 / 15moat 0.5/10
Premium11 / 20implied volatility 97%
Stability8 / 20176k shares/day, $64M cap, beta -0.88

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 12 Nov 2026 (before the open), 27 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Biotechnology

The 12 companies below are the closest to Cingulate Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
FBIO
Fortress Biotech, Inc.
1.9174.01+97%54Fair$64M
SPRO
Spero Therapeutics, Inc.
1.123.81+71%56Fair$65M
AURX
Nuo Therapeutics, Inc.
1.28--25No options$62M
VRCA
Verrica Pharmaceuticals Inc.
3.83--40Weak$66M
XBIT
XBiotech Inc.
2.164.08+47%36Weak$66M
HYFT
MindWalk Holdings Corp.
1.40--34Weak$66M
OSTX
OS Therapies Incorporated
1.41--26No options$66M
PMVP
PMV Pharmaceuticals, Inc.
1.240.6530-90%18Weak$66M
APLM
Apollomics, Inc.
21.00--28No options$61M
CSBR
Champions Oncology, Inc.
4.793.89-23%24Weak$67M
TLSA
Tiziana Life Sciences Ltd
1.050.0186-5553%20Weak$67M
BMEA
Biomea Fusion, Inc.
0.83640.9797+15%40Weak$60M

⚖ Compare CING with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about CING

Is CING undervalued right now?

No: at 4.39 the stock trades 8592% above the GLS average fair value of 0.0505 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of CING and what does it mean?

CING scores 24 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for CING?

0.0505 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Cingulate Inc. report earnings next?

The next earnings report is due on 12 Nov 2026 (before the open), 27 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does CING have listed options, and how liquid are they?

Yes. The nightly snapshot found 40 listed contracts with 13,276 open interest across all expiries and implied volatility of 97% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.